The FDA-cleared PrecivityAD2® test is now available to order

PrecivityAD2® Test Clinical Data

The Evolution of the PrecivityAD2® Test: Rigorously Studied in Multiple Populations and Clinical Settings

Single Cutoff. External Validation¹: Independently validated performance of 90% sensitivity and 92% specificity for identifying brain amyloid plaques. Clinical Use in Specialty Care²: With increased confidence following testing, specialty care physicians planned changes to drug prescribing and additional amyloid assessment.Two Cutoffs. Clinical Validation³: Highly accurate results concordant with amyloid PET imaging and CSF biomarkers that were not influenced by patient age and sex. High test performance across clinical stages of disease (SCD, MCI, and dementia). Test performance unaffected by the number of comorbidities a patient has.

Validated in PrecivityAD2 single-cutoff test.

Single-cutoff test

The PrecivityAD2® Test Was Externally Validated in Individuals With MCI and Dementia

Study Design

External validation occurred using data from a recent head-to-head study (FNIH-ADNI) of different blood test performance in CI and CU individuals. This study evaluated data from CI individuals (N=191) only.1

Study Objective

Perform clinical validation of the PrecivityAD2® test in a second, independent cohort to evaluate the repeatability, reliability, and accuracy of the PrecivityAD2® test in the intended use population.1

Results

(Concordance with amyloid PET)1

The PrecivityAD2® test was highly accurate (91%) in discerning amyloid PET positive and negative status in symptomatic individuals.

Sensitivity: 90%Specificity: 92%

The PrecivityAD2® single-cutoff test exceeds clinical guideline performance standards (≥90% sensitivity and specificity) for blood tests intended to assist in making an AD diagnosis.1,4-6

Single-cutoff test

The PrecivityAD2® Test Can Help Optimize Clinical Decision-Making2

The QUIP-II study evaluated clinical use of the PrecivityAD2® test and changes in clinical confidence and planned management in 203 patients in real-world settings.

Clinicians learned how to use the test2

Clinicians used the test appropriately2

Test results improved diagnostic certainty2

With a negative APS2 result, the clinician-reported probability for an AD diagnosis decreased from:

53%
11%

Clinicians were more certain patients did not have AD after they observed a negative test result.

With a positive APS2 result, the clinician-reported probability for an AD diagnosis increased from:

65%
93%

Clinicians were more certain patients had AD after they observed a positive test result.

Test results were clinically impactful and changed planned prescribing2

59%

of all patients had a planned medication change

119/203, P<.0001 vs prespecified threshold of 20% change

Bar chart: Change in Planned Medication Use From Baseline After Reviewing PrecivityAD2® Results. APS2 (-): 77% at baseline, 20% after post-test results. APS2 (+): 71% at baseline, 96% after post-test results.

Test results impacted clinicians’ medical decisions2

33%

of all patients had a change in planned brain amyloid evaluation

68/203, P<.0001 vs prespecified threshold of 20% change

Bar chart: Change in Planned Additional Amyloid Brain Amyloid Evaluation From Baseline After Reviewing the PrecivityAD2® Test Results. APS2 (-): 43% at baseline, 13% after post-test results. APS2 (+): 35% at baseline, 26% after post-test results.

FDA-cleared two-cutoff test

The PrecivityAD2® Test Two-Cutoff Evolution: High PPVs and NPVs, Interpretable Insights

The performance of the PrecivityAD2® test was assessed in plasma samples from 1142 individuals with signs or symptoms of cognitive impairment from 3 cohorts.3

Table of two-cutoff APS2 results. Columns: APS2³; PPV/NPV³ᵃ; Frequency of Result³; Likelihood Ratio (LR)³; LR Interpretation⁷. Positive (APS2>66.5): 97.6% (PPV); 37%; 37.05; >10, very useful in establishing the presence of amyloid pathology. Likely Positive (APS2 27.5–66.5): 77.3% (PPV); 17.3%; 3.05; >1, result more likely to occur in those with amyloid pathology than those without. Negative (APS2<27.5): 93.1% (NPV)ᵇ; 45.6%; 0.07; <0.1, very useful in ruling out the presence of amyloid pathology.

aPositive predictive value (PPV) for Positive and Likely Positive results correspond to the predictive value (PV) while the negative predictive value (NPV) for Negative results is calculated as 100%-PV.

bDerived from 6.9% PV for brain amyloid pathology in Negative results reported in labeling.

Most patients (82.7%) had a clear positive or negative APS2 test result, reducing uncertainty and informing next steps.3

An APS2 test result provides clinicians with an actionable path forward to discuss care options with patients and their care partners.3,4

The PrecivityAD2® Test Demonstrates High Positive and Negative Predictive Value Regardless of a Patient’s Medical Complexity3*

Clinical performance by patient comorbidity: The PrecivityAD2® test was validated across 12 documented comorbidities.

Atrial Fibrillation

Autoimmune/
Inflammatory Disease

Chronic
Heart Failure

Chronic
Kidney Disease

Coronary
Heart Disease

Depression

Diabetes

Dyslipidemia

History of Cancer

History of Stroke or TIA

Hypertension

Obesity

Interpreting the PrecivityAD2® Test Report

Results Within 10 Business Days

The FDA-Cleared PrecivityAD2® Test Can Empower Timely and Accurate AD Diagnosis to Aid in Patient Care

Not all blood tests are created equal; the clinically validated, FDA-cleared PrecivityAD2® test measures %p-tau217 and Aβ42/40 to optimize performance, regardless of comorbidities3

Mass spectrometry, a gold-standard diagnostic technology, powers the PrecivityAD2® test and has many advantages over traditional immunoassay-based tests8-10

The PrecivityAD2® test was validated across clinical characteristics and meets current recommendations and guidelines3

Test Updates³. New two-cutoff APS2 delivers >90% PPV and NPV for positive and negative results, consistent with the presence or absence of brain amyloid pathology. A likely positive APS2 result indicated ~3 in 4 participants had brain amyloid pathology; can inform next steps for patients undergoing an AD evaluation.

Indications for ordering: Use in patients aged 40 and older who present with signs or symptoms of cognitive impairment undergoing evaluation for Alzheimer’s disease or other forms of cognitive decline.3

Limitations and Warnings

Limitations

  • The PrecivityAD2® test is for prescription use only
  • The PrecivityAD2® test is for in vitro diagnostic use: only performed at C2N Diagnostics Laboratory
  • This test is intended to be performed only on qualified, serial number-controlled instruments at C2N Diagnostics Laboratory. All instruments used for patient testing are controlled under C2N’s Quality Management System and must successfully complete the required qualification and validation activities before implementation
  • Always interpret the PrecivityAD2® test in conjunction with the patient’s medical history, clinical presentation, physical assessment, and other findings
  • The safety and effectiveness of the PrecivityAD2® test have not been established for:
    • Predicting development of dementia or other neurologic conditions
    • Monitoring responses to therapies
  • The performance of the PrecivityAD2® test across racial subgroups has not been fully established because of the relatively small number of subjects who report racial categories other than White and the large proportion of subjects in the Pooled Validation Cohort with missing racial categorization. Results for these subgroups should be interpreted with caution

Warnings

  • Erroneous results may occur due to improper specimen collection, handling, storage, shipping, or unevaluated interfering substances
  • Hemoglobin concentration >150 mg/dL may interfere with analyte measurement and affect the APS2 result
ADNI, Alzheimer's Disease Neuroimaging Initiative; CI, cognitively impaired; CU, cognitively unimpaired; FNIH, Foundation for the National Institutes of Health; NPV, negative predictive value; PPV, positive predictive value.

Prevalence of amyloid PET positivity: 56%. Amyloid PET scan positivity was defined as Centiloid (CL) score (quantitative PET) >25.
References

1. Coppinger J, West T, Kirmess KM, et al. Independent validation of the PrecivityAD2™ blood test to identify presence or absence of brain amyloid pathology in individuals with cognitive impairment. NPJ Dementia. 2025;1(23). doi: 10.1038/s44400-025-00026-y. 2. Monane M, Maraganore DM, Carlile RM, et al. Clinical utility of an Alzheimer’s disease blood test among cognitively impaired patients: results from the quality improvement PrecivityAD2 (QUIP II) clinician survey study. Diagnostics (Basel). 2025;15(2):167. doi:10.3390/diagnostics15020167. 3. PrecivityAD2 [package insert]. St. Louis, MO: C2N Diagnostics; 2026. 4. Schindler SE, Galasko D, Pereira AC, et al. Acceptable performance of blood biomarker tests of amyloid pathology - recommendations from the Global CEO Initiative on Alzheimer’s disease. Nat Rev Neurol. 2024;20(7):426-439. doi:10.1038/s41582-024-00977-5. 5. Jack CR, Andrews JS, Beach TG, et al. Alzheimers Dement. Revised criteria for diagnosis and staging of Alzheimer’s disease: Alzheimer’s Association workgroup. 2024;20(8):5143-5169. doi:10.1002/alz.13859. 6. Palmqvist S, Whitson HE, Allen LA, et al. Alzheimer’s Association clinical practice guideline on the use of blood-based biomarkers in the diagnostic workup of suspected Alzheimer’s disease within specialized care settings. Alzheimers Dement. 2025;21(7):e70535. doi:10.1002/alz.70535. 7. Ranganathan P, Aggarwal R. Understanding the properties of diagnostic tests - Part 2: Likelihood ratios. Perspect Clin Res. 2018;9(2):99-102. doi:10.4103/picr.PICR_41_18. 8. Eastwood SM, Meyer MR, Kirmess KM, et al. PrecivityAD2™ Blood Test: Analytical Validation of an LC-MS/MS Assay for Quantifying Plasma Phospho-tau217 and Non-Phospho-tau217 Peptide Concentrations That Are Used with Plasma Amyloid-β42/40 in a Multianalyte Assay with Algorithmic Analysis for Detecting Brain Amyloid Pathology. Diagnostics (Basel). 2024;14(16):1739-1756. 9. Teunissen CE, Kimble L, Bayoumy S, et al. Methods to Discover and Validate Biofluid-Based Biomarkers in Neurodegenerative Dementias. Mol Cell Proteomics. 2023;22(10):100629. 10. Bravo-Veyrat S, Hopfgartner G. Mass spectrometry based high-throughput bioanalysis of low molecular weight compounds: are we ready to support personalized medicine?. Anal Bioanal Chem. 2022;414(1):181-192. doi:10.1007/s00216-021-03583-2.